in5points
BusinessAsianet Newsable

TG Therapeutics CEO Says Briumvi Is On Track To Become A $1B US Drug – Retail Shrugs Off EPS Miss

in5points

  1. TG Therapeutics CEO says Briumvi is on track to become a $1B US drug.

  2. TG Therapeutics raised its 2026 total global revenue target to about $950 million, up from $925 million.

  3. Retail investors shrugged off the EPS miss.

3h ago · original ↗
TG Therapeutics CEO Says Briumvi Is On Track To Become A $1B US Drug – Retail Shrugs Off EPS Miss · in5points